Author

A. R. Keller

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Biophysics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:proteomics· 2 Approach:biophysical modeling· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

A. E. Atang· 2 shared A. W. Avery· 2 shared S. A. Denha· 2 shared A. L. Carter· 1 shared B. Svensson· 1 shared D. D. Thomas· 1 shared P. Guhathakurta· 1 shared R. T. Rebbeck· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

9 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

A. E. Atang

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Increased actin binding is a shared molecular consequence of numerous spinocerebellar ataxia mutations in β-III-spectrin

A. E. Atang, A. R. Keller, S. A. Denha, A. W. Avery

This study shows that multiple SCA5 mutations increase actin-binding affinity, with some mutations causing earlier symptom onset.

bioRxiv · Feb 20, 2023 · PreprintBiochemistry

Identification of β-III-spectrin actin-binding modulators for treatment of spinocerebellar ataxia

P. Guhathakurta, R. T. Rebbeck, S. A. Denha, A. R. Keller, A. L. Carter, A. E. Atang, B. Svensson, D. D. Thomas, T. S. Hays, A. W. Avery

The paper develops an in vitro FRET assay to identify small molecule modulators of the L253P mutant β-III-spectrin actin-binding domain, identifying potential drug candidates for SCA5 treatment.

bioRxiv · Nov 8, 2022 · PreprintBiophysics